摘要
司帕沙星（ｓｐａｒｆｌｏｘａｃｉｎ，ＳＰＬＸ）是一新喹诺酮类抗菌药物。本试验采取随机对照方法，评价了司帕沙星治疗呼吸系统感染的有效性与安全性，选用氧氟沙星为对照。两组共治疗患者８０例，每组各４０例。结果显示，司帕沙星组与氧氟沙星组有效率分别为８７．５％和８５％，细菌清除率分别为８６．１％与８６．１％，不良反应发生率分别为７．５％和１０％，以上结果统计学均无显著性差异（Ｐ＞０．０５）。司帕沙星与氧氟沙星等６种抗菌药物的体外抗菌活性比较显示，司帕沙星对革兰氏阳性菌的ＭＩＣ９０值≤０．２５ｍｇ／Ｌ，体外抗菌活性高于氧氟沙星；对大多数革兰氏阴性菌具有良好的体外抗菌活性，与氧氟沙星相似。试验表明，司帕沙星是一个高效、安全的抗菌药物，治疗呼吸系统感染疗效肯定。
Sparfloxacin is a new quinolone antibacterial agent. A randomized controlled clinical trial was conducted to evaluate the efficacy and safety of sparfloxacin in the treatment of respiratory tract infections. Ofloxacin was served as the control drug. A total of 80 patients included in the study, 40 cases in each group. Results showed that the overall efficacy rated of sparflocacin and ofloxacin were 87.5% and 85%, and the bacterial clearance rates were 86.1% and 86.1%, respectively. The adverse drug reaction rates of sparfloxacin and ofloxacin were 7.5% and 10%. There were no statistical significant difference between the two groups. The results of in vitro activities of sparfloxacin as compared with other 5 antibacterial agents showed that the activities of sparfloxacin against Gram positive organisms (MIC 90 ≤0.25mg/L) were generally higher than those of ofloxacin. Sparfloxacin had good activities against many Gram negative organisms and was similar to that of ofloxacin. it was concluded that sparfloxacin is a highly effective and safe broad spectrum antibacterial agent for the treatment of respiratory tract infections.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
1999年第1期71-76,共6页
Chinese Journal of Antibiotics
关键词
司帕沙星
氧氟沙星
随机对照临床试验
呼吸系统感染
Sparfloxacin
Ofloxacin
Randomized controlled clinical trial
Respiratory tract infections
